Skip to content

Homoeopathic treatment of depression

Efficacy of Individualized Homoeopathic Medicines in Treatment of Moderate Depression: A Double-blind, Randomized, Placebo-controlled Clinical Trial

Status
Recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/05/014102
Enrollment
120
Registered
2018-05-25
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Moderate depression

Interventions

Intervention1: Individualized homoeopathic medicines in centesimal potencies plus psychological counselling: In centesimal potencies, each dose shall consist of 4 cane sugar globules no. 10 medicated
indistinguishable from verum. To be taken thrice a day orally on clean tongue in empty stomach. Along with, standard psychological counselling will be given. Duration of therapy: 4 months

Sponsors

National Institute of Homoeopathy Ministry of AYUSH Govt of India
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Cases suffering from depression, diagnosed as per DSM-V criteria [18] 2. Moderate cases of depression (HRDS scores 14 to 18) 3. Patients must not have been taking antidepressants or anxiolytic drugs at the time of inclusion 4. Both male and female patients 5. Age between 18 and 65 years 6. Capability and willingness to give informed consent and to comply with the study procedures 7. Literate patients who can read English and/or Bengali

Exclusion criteria

Exclusion criteria: 1. Mild (HRDS 13 or less) cases of depression 2. Severe or very severe depression (HRDS more than 19); with or without suicide attempt 3. Spontaneous improvement by 25% or more in HDRS during the 1-week placebo run-in prior trial enrolment 4. Patients with other psychiatric diseases; e.g. schizophrenia or other psychotic disorders, bipolar affective disorder, schizoaffective disorders, alcohol or other substance abuse, eating disorders, psychosis, mania, hypomania or any other Axis I disorder except panic disorder, personality disorders, history of seizures 5. A clinically significant acute or chronic disease that would hinder regular participation in the study 6. Treatment with antipsychotics, antidepressants, sedatives/hypnotics or mood stabilizers four weeks prior to the screening 7. Complementary or alternative treatment used simultaneously to the study (for example acupuncture, phytotherapy, psychotherapy etc.) 8. Homeopathic treatment for any chronic diseases eight weeks prior to study entry 9. Cases suffering from uncontrolled systemic illness or life-threatening infections 10. Self-reported immune-compromised state 11. Pregnant women and lactating mothers

Design outcomes

Primary

MeasureTime frame
Hamiltonâ??s Depression Rating Scale (HDRS)Timepoint: Baseline, every month, up to 3 months

Secondary

MeasureTime frame
Beckâ??s Depression Inventory (BDI)Timepoint: Baseline, every month, up to 3 months;Montgomery-Ã?sberg Depression Scale (MADRS)Timepoint: Baseline, every month, up to 3 months;Patients Health Questionnaire â?? 9 (PHQ-9)Timepoint: Baseline, every month, up to 3 months

Countries

India

Contacts

Public ContactHarcharanjeet Kaur

SGT University

dr.harcharan@gmail.com9810018876

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026